Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Vismodegib
Drug ID BADD_D02365
Description Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Indications and Usage Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Marketing Status approved; investigational
ATC Code L01XJ01
DrugBank ID DB08828
KEGG ID D09992
MeSH ID C538724
PubChem ID 24776445
TTD Drug ID D03EDQ
NDC Product Code 50242-140
UNII 25X868M3DS
Synonyms HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616
Chemical Information
Molecular Formula C19H14Cl2N2O3S
CAS Registry Number 879085-55-9
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholestasis09.01.01.0010.000224%Not Available
Chromaturia20.02.01.0020.000302%
Colitis07.08.01.0010.000683%
Colon cancer16.13.01.001; 07.21.01.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.0010.006816%
Cyst08.03.05.001; 16.02.02.0020.000571%Not Available
Deafness04.02.01.0010.000604%Not Available
Death08.04.01.0010.016297%
Dehydration14.05.05.0010.003537%
Dementia19.20.02.001; 17.03.01.0010.001477%Not Available
Dementia Alzheimer's type17.03.06.001; 19.20.03.0010.000168%Not Available
Dermatitis23.03.04.0020.000437%Not Available
Diarrhoea07.02.01.0010.016185%
Distractibility19.21.02.0070.000381%Not Available
Duodenal ulcer07.04.02.0020.000168%
Dysgeusia17.02.07.003; 07.14.03.0010.035839%
Dyspepsia07.01.02.0010.002015%
Dysphagia07.01.06.0030.005082%
Ectropion23.07.05.001; 06.06.04.0010.000437%Not Available
Electrolyte imbalance14.05.01.0020.000280%Not Available
Eosinophilia01.02.04.0010.000302%
Epiphyses premature fusion15.02.02.001; 05.05.03.0020.000168%Not Available
Eye disorder06.08.03.001--Not Available
Faeces discoloured07.01.03.0020.000302%Not Available
Failure to thrive19.07.05.001; 14.03.02.008; 18.04.01.0030.000112%Not Available
Fatigue08.01.01.0020.021815%
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.007--
Gastric ulcer07.04.03.0020.000224%
Gastrointestinal carcinoma16.13.04.001; 07.21.03.0010.000112%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages